Suven Life Sciences Intrinsic Value
SUVEN • Healthcare
Current Stock Price
₹166.87
Primary Intrinsic Value
₹100.00
Market Cap
₹367.1 Cr
-40.1%
Downside
Median Value
₹100.00
Value Range
₹50 - ₹100
Assessment
Trading Above Calculated Value
Safety Margin
-66.9%
SUVEN Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹100.00 | ₹90.00 - ₹110.00 | -40.1% | Book Value/Share: ₹50.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹50.06 | ₹45.05 - ₹55.07 | -70.0% | Revenue/Share: ₹9.09, P/S: 2.0x |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
SUVEN Intrinsic Value Analysis
What is the intrinsic value of SUVEN?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Suven Life Sciences (SUVEN) is ₹100.00 (median value). With the current market price of ₹166.87, this represents a -40.1% variance from our estimated fair value.
The valuation range spans from ₹50.06 to ₹100.00, indicating ₹50.06 - ₹100.00.
Is SUVEN undervalued or overvalued?
Based on our multi-method analysis, Suven Life Sciences (SUVEN) appears to be trading above calculated value by approximately 40.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 38.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -280.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -8671.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.15x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Suven Life Sciences
Additional stock information and data for SUVEN
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-154 Cr | ₹-154 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-116 Cr | ₹-116 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-116 Cr | ₹-240 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-128 Cr | ₹-139 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹-96 Cr | ₹-96 Cr | Negative Cash Flow | 3/10 |